MedPage Today on MSN
Tenecteplase unseats low-dose alteplase favored for Asian patients
Japanese trial compared lytics for bridging before endovascular thrombectomy ...
Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...
When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...
Please provide your email address to receive an email when new articles are posted on . Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset ...
PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...
DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial ...
LOS ANGELES -- Tenecteplase (TNKase) is a more powerful thrombolytic for large vessel acute ischemic stroke than alteplase (Activase) but just as safe, the EXTEND-IA TNK trial showed. Tenecteplase ...
The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...
A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a decades-old medication used by most hospitals in the U.S. and could hold ...
LOS ANGELES — Not only is tenecteplase a cheaper and more convenient thrombolytic agent than alteplase, but new research suggests it also leads to better outcomes in stroke patients selected for ...
No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase seems to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results